Lachlan Brown
Stock Analyst at William Blair
(2.05)
# 3,042
Out of 4,996 analysts
10
Total ratings
37.5%
Success rate
10.82%
Average return
Main Sectors:
Stocks Rated by Lachlan Brown
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MANH Manhattan Associates | Downgrades: Neutral | $270 → $200 | $211.56 | -5.46% | 2 | Jun 10, 2025 | |
| HROW Harrow | Initiates: Outperform | n/a | $47.10 | - | 1 | Jun 10, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Outperform | n/a | $5.61 | - | 1 | Apr 8, 2025 | |
| OCUL Ocular Therapeutix | Initiates: Outperform | n/a | $12.53 | - | 1 | Apr 8, 2025 | |
| SNPS Synopsys | Initiates: Buy | $600 | $487.76 | +23.01% | 1 | Jan 13, 2025 | |
| CDNS Cadence Design Systems | Initiates: Buy | $350 | $350.11 | -0.03% | 1 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Outperform | n/a | $22.39 | - | 1 | Oct 16, 2024 | |
| DSGX The Descartes Systems Group | Initiates: Neutral | $90 | $94.94 | -5.20% | 1 | May 14, 2024 | |
| SPSC SPS Commerce | Initiates: Buy | $220 | $106.32 | +106.92% | 1 | May 14, 2024 |
Manhattan Associates
Jun 10, 2025
Downgrades: Neutral
Price Target: $270 → $200
Current: $211.56
Upside: -5.46%
Harrow
Jun 10, 2025
Initiates: Outperform
Price Target: n/a
Current: $47.10
Upside: -
Kalaris Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $5.61
Upside: -
Ocular Therapeutix
Apr 8, 2025
Initiates: Outperform
Price Target: n/a
Current: $12.53
Upside: -
Synopsys
Jan 13, 2025
Initiates: Buy
Price Target: $600
Current: $487.76
Upside: +23.01%
Cadence Design Systems
Jan 13, 2025
Initiates: Buy
Price Target: $350
Current: $350.11
Upside: -0.03%
Apellis Pharmaceuticals
Oct 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $22.39
Upside: -
The Descartes Systems Group
May 14, 2024
Initiates: Neutral
Price Target: $90
Current: $94.94
Upside: -5.20%
SPS Commerce
May 14, 2024
Initiates: Buy
Price Target: $220
Current: $106.32
Upside: +106.92%